Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease
Authors:
Open Access
- 1 April 2018
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 62 (4) , e01909-17
Abstract
Current therapeutic options for cryptococcal meningitis are limited by toxicity, global supply, and emergence of resistance. There is an urgent need to develop additional antifungal agents that are fungicidal within the central nervous system and preferably orally bioavailable. The benzimidazoles have broad-spectrum antiparasitic activity but also have in vitro antifungal activity that includes Cryptococcus neoformans . Flubendazole (a benzimidazole) has been reformulated by Janssen Pharmaceutica as an amorphous solid drug nanodispersion to develop an orally bioavailable medicine for the treatment of neglected tropical diseases such as onchocerciasis. We investigated the in vitro activity, the structure-activity-relationships, and both in vitro and in vivo pharmacodynamics of flubendazole for cryptococcal meningitis. Flubendazole has potent in vitro activity against Cryptococcus neoformans , with a modal MIC of 0.125 mg/liter using European Committee on Antimicrobial Susceptibility Testing (EUCAST) methodology. Computer models provided an insight into the residues responsible for the binding of flubendazole to cryptococcal β-tubulin. Rapid fungicidal activity was evident in a hollow-fiber infection model of cryptococcal meningitis. The solid drug nanodispersion was orally bioavailable in mice with higher drug exposure in the cerebrum. The maximal dose of flubendazole (12 mg/kg of body weight/day) orally resulted in an ∼2 log 10 CFU/g reduction in fungal burden compared with that in vehicle-treated controls. Flubendazole was orally bioavailable in rabbits, but there were no quantifiable drug concentrations in the cerebrospinal fluid (CSF) or cerebrum and no antifungal activity was demonstrated in either CSF or cerebrum. These studies provide evidence for the further study and development of the benzimidazole scaffold for the treatment of cryptococcal meningitis.Keywords
Funding Information
- DH | National Institute for Health Research (CS/08/08)
- RCUK | Medical Research Council (MR/N023005/1)
This publication has 32 references indexed in Scilit:
- Crystal structure of a complex of human chymase with its benzimidazole derived inhibitorJournal of Synchrotron Radiation, 2013
- ZINCPharmer: pharmacophore search of the ZINC databaseNucleic Acids Research, 2012
- Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitorsBioorganic & Medicinal Chemistry, 2011
- Therapy for fungal diseases: opportunities and prioritiesTrends in Microbiology, 2010
- Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2010
- New Tubulin Inhibitors from Plants – A Critical AssessmentChimia, 2007
- Symptomatic Relapse of HIV‐Associated Cryptococcal Meningitis after Initial Fluconazole Monotherapy: The Role of Fluconazole Resistance and Immune ReconstitutionClinical Infectious Diseases, 2006
- β-Tubulin genes and the basts for benzimidazole sensitivity of the opportunistic fungus Cryptococcus neoformansMicrobiology, 1997
- Effects of 10 known or suspected spindle poisons in the in vitro porcine brain tubulin assembly assayMutagenesis, 1991
- Combination Therapy of Experimental Candidiasis, Cryptococcosis and Aspergillosis in MiceChemotherapy, 1982